Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Research And Development Expense of $7.96 million for the year ending 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +15.7% in Research And Development Expense from 2024 to 2025.
- This data is from ELITE PHARMACEUTICALS INC /NV/'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), ELITE PHARMACEUTICALS INC /NV/'s Research And Development Expense has grown by 475.0%.
- Historical annual values: Fiscal year 2025: $7.96 million | Fiscal year 2024: $6.88 million | Fiscal year 2023: $6.20 million | Fiscal year 2022: $4.05 million | Fiscal year 2021: $5.11 million | Fiscal year 2020: $5.53 million | Fiscal year 2019: $7.60 million | Fiscal year 2018: $9.62 million | Fiscal year 2017: $8.30 million | Fiscal year 2016: $12.43 million | Fiscal year 2015: $14.73 million | Fiscal year 2014: $3.96 million | Fiscal year 2013: $975.3 thousand | Fiscal year 2012: $1.74 million | Fiscal year 2011: $1.39 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: